Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lava Therapeutics N.V. (NQ: LVTX )

2.830 -0.110 (-3.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lava Therapeutics N.V.

< Previous 1 2 Next >
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
From FN Media Group LLC
Via GlobeNewswire
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023 
From LAVA Therapeutics N.V.
Via GlobeNewswire
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
Exposures Pension
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
From LAVA Therapeutics N.V.
Via GlobeNewswire
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Announces Annual Meeting of Shareholders
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Appointment of New Directors to the Board
Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board 
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts 
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223
LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development 
Via Spotlight Growth
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.